Business context and reporting period
The filing is for Net 1 UEPS Technologies, Inc., not Lesaka Technologies Inc. It covers the three months ended September 30, 2012—fiscal Q1 2013, rather than calendar or fiscal Q1 2012. Amounts below are U.S. dollars unless noted; financial statement amounts are in millions, except per-share data.
Net1 provides transaction processing, social welfare grant payment services, smart-card accounts, financial services, and related technology. Its largest activity is South African transaction-based services, including the SASSA social-grant contract.
Key financial metrics
| Metric | Quarter ended Sep. 30, 2012 | Prior-year quarter |
|---|---|---|
| Revenue | $111.7 million | $99.9 million |
| Operating income / margin | $9.3 million / 8.3% | $30.8 million / 30.9% |
| Net income attributable to Net1 | $6.7 million | $19.8 million |
| Diluted earnings per share | $0.15 | $0.44 |
| Operating cash flow | $25.7 million | $27.2 million |
| Cash and cash equivalents, Sep. 30 | $57.5 million | $102.0 million |
Revenue increased 12% in reported dollars; management said it rose 30% in South African rand, reflecting SASSA and higher KSNET contribution. Cost of goods sold and support expense increased 37%, while selling, general and administrative expense rose 75%. Profitability contracted sharply as SASSA implementation costs increased and the prior-year quarter included a $4.0 million noncash gain on liquidation of SmartSwitch Nigeria. The effective tax rate was 36.0%, versus 34.9%.
Cash increased $18.4 million from June 30, 2012. Investing cash flow was positive $53.1 million, largely reflecting a $60.8 million decrease in settlement assets; financing cash flow was negative $60.5 million, largely reflecting the matching decrease in settlement obligations. These settlement balances relate to funds held for beneficiaries, healthcare providers, and payroll payees and should not be treated as unrestricted liquidity.
Total assets were $916.1 million and total liabilities were $557.8 million at September 30. Long-term borrowings were $96.6 million, including $14.4 million classified as current. The Korean secured facility carried a 7.64% rate. A separate South African short-term facility of approximately $30.1 million was undrawn. Management said cash and available facilities were sufficient for at least the next four quarters.
Material changes and operating developments
- South African transaction-based revenue rose 23% in reported dollars, while segment operating income fell 68%. Management attributed margin pressure primarily to SASSA implementation costs and higher, lower-margin prepaid airtime sales.
- SASSA enrollment involved a materially larger beneficiary population than initially estimated: the estimate rose from about 15.5 million to 21.6 million. By quarter-end, Net1 had enrolled about 1.7 million grant recipients and 1.3 million associated beneficiaries. It increased temporary staff from 2,500 to 5,500. Pricing is based on grant recipients paid, not additional beneficiaries enrolled.
- Net1 recorded $14.1 million of direct SASSA implementation expenses and separately expensed $1.7 million of smart cards issued. Quarter capital expenditure was $6.45 million; management estimated cumulative implementation-related capital expenditure would be around $35 million.
- International transaction-based activities reported an operating loss of $0.2 million, compared with income of $0.7 million. Management cited currency effects, XeoHealth start-up costs, mobile virtual card activity, and continuing Net1 Virtual Card losses, partly offset by KSNET and Iraq revenue.
- On September 14, Net1 acquired Pbel for approximately $3.8 million: $1.9 million cash paid and the remainder potentially payable in shares subject to performance milestones. Pbel supports mobile virtual card and related technology initiatives. Its purchase-price allocation remained preliminary.
Outlook, risks, contingencies, and unusual items
- Net1 planned to substantially complete the second SASSA enrollment phase by March 2013. Management expected to retain 1,200–1,500 temporary employees permanently after enrollment. No quantified earnings or revenue guidance was provided.
- Management expected North Dakota XeoHealth audit revenue in fiscal Q2 2013, but could not quantify it; Missouri services were expected to begin in fiscal Q3, subject to customer sign-off. VCPay development with partners in India and Spain was underway, with introduction planned in calendar 2013.
- The SASSA tender award remained subject to litigation. The High Court ruled the contract would not be set aside but found the tender process illegal and invalid; appeals were pending. On November 1, 2012, the Constitutional Court dismissed AllPay’s request for a direct appeal at that stage. The ultimate outcome remained uncertain.
- Key exposures include U.S. dollar translation effects on largely rand-denominated operations, interest-rate and counterparty risks, and insurance risks at Smart Life, including reinsurance availability, claims experience, pricing assumptions, and competition.
- Other items to note: the company acquired Pbel from entities related to its CEO and his son; stock-based compensation increased to $1.1 million from $0.5 million; and unrecognized tax benefits increased by $1.1 million during the quarter.
Important facts for investors to verify
- Confirm the issuer and period: the supplied filing is Net 1 UEPS Technologies, Inc.’s quarter ended September 30, 2012, not a Lesaka Technologies filing.
- Track SASSA enrollment progress, implementation spending, staffing, card costs, and whether the larger beneficiary count affects execution or margins despite no added compensation for non-recipient beneficiaries.
- Follow the SASSA appeal proceedings and their potential effect on the contract.
- Assess whether revenue growth can translate into operating-margin recovery after implementation costs, and distinguish underlying rand trends from U.S. dollar translation effects.
- Review debt repayment, cash availability excluding settlement funds, capital commitments, and the uncertain timing and value of XeoHealth revenues.